<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077620</url>
  </required_header>
  <id_info>
    <org_study_id>201602165</org_study_id>
    <nct_id>NCT03077620</nct_id>
  </id_info>
  <brief_title>Sleep Quality and Amyloid-Beta Kinetics</brief_title>
  <official_title>Sleep Quality and Amyloid-Beta Kinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to change the concentration of amyloid-beta in human&#xD;
      cerebrospinal fluid (CSF) by modification of sleep efficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to investigate whether or not increasing sleep efficiency will&#xD;
      change the concentration of amyloid-beta in cerebrospinal fluid (CSF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Amyloid-beta (Abeta) production, clearance, and concentration in the CSF (cerebral spinal fluid) of individuals with poor sleep efficiency as measured by ng/ml.</measure>
    <time_frame>36 hours of CSF collection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Amyloid-beta (Abeta) production, clearance, and concentrations in the CSF (cerebral spinal fluid) following pharmacologic sleep induction.induction in individuals with poor sleep efficiency.</measure>
    <time_frame>36 hours of CSF collection</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amyloid-beta</condition>
  <arm_group>
    <arm_group_label>Poor sleep group treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg Suvorexant tablet h.s. for two consecutive nights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor sleep group control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Good sleep group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor sleep group treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg Suvorexant tablet h.s. for two consecutive nights</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.</description>
    <arm_group_label>Poor sleep group treatment 1</arm_group_label>
    <arm_group_label>Poor sleep group treatment 2</arm_group_label>
    <other_name>Belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.</description>
    <arm_group_label>Good sleep group</arm_group_label>
    <arm_group_label>Poor sleep group control</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 45-65 years&#xD;
&#xD;
          -  Any sex&#xD;
&#xD;
          -  Any race/ethnicity&#xD;
&#xD;
          -  Mini-Mental Status Examination score (MMSE) &gt;=27&#xD;
&#xD;
          -  Sleep efficiency measured by actigraphy to determine good sleeper or poor sleeper&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitive impairment as determined by history of MMSE &lt; 27&#xD;
&#xD;
          -  Inability to speak or understand English&#xD;
&#xD;
          -  BMI &gt;35&#xD;
&#xD;
          -  Any sleep disorders other than insomnia&#xD;
&#xD;
          -  history of sleep-disordered breathing&#xD;
&#xD;
          -  STOP-Bang score &gt; 3&#xD;
&#xD;
          -  History or reported symptoms suggestive of restless legs syndrome, narcolepsy or other&#xD;
             sleep disorders&#xD;
&#xD;
          -  Sleep schedule outside the range of bedtime 8PM-12AM and wake time 4AM-9AM&#xD;
&#xD;
          -  Contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to&#xD;
             lidocaine or disinfectant; prior central nervous system or lower back surgery)&#xD;
&#xD;
          -  Cardiovascular disease requiring medication except for controlled hypertension (PI&#xD;
             discretion)&#xD;
&#xD;
          -  Stroke&#xD;
&#xD;
          -  Hepatic or renal impairment&#xD;
&#xD;
          -  Pulmonary disease (PI discretion)&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  HIV or AIDS&#xD;
&#xD;
          -  Neurologic or psychiatric disorder requiring medication (PI discretion)&#xD;
&#xD;
          -  Alcohol or tobacco use (PI discretion)&#xD;
&#xD;
          -  Use of sedating medications&#xD;
&#xD;
          -  Inability to get out of bed independently&#xD;
&#xD;
          -  Abnormal movement of the non-dominant arm (would affect actigraphy data in&#xD;
             unpredictable ways)&#xD;
&#xD;
          -  Abnormal physical examination&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  History of migraine headaches (PI discretion)&#xD;
&#xD;
          -  History of drug abuse in the past 6 months&#xD;
&#xD;
          -  Urinary or fecal incontinence&#xD;
&#xD;
          -  Difficulty sleeping in an unfamiliar environment (good sleep quality group only)&#xD;
&#xD;
          -  History or presence of any clinically significant medication condition, behavioral or&#xD;
             psychiatric condition (including suicidal ideation), or surgical history based on&#xD;
             medical record or patient report that could affect the safety of the subject or&#xD;
             interfere with study assessments or in the judgment of the PI is not a good candidate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Lucey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Toedebusch, BS</last_name>
    <phone>314-747-0646</phone>
    <email>toedebuschc@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Toedebusch, BS</last_name>
      <phone>314-747-0646</phone>
      <email>toedebuschc@neuro.wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

